[The effect of imatinib for gastrointestinal tumor].
Long-term survival in patients with gastrointestinal stromal tumors (GIST) was very rare. Recently treatment with imatinib mesylate, a molecular targeted agent that inhibits the KIT tyrosine kinase receptor showed 81.6% of outstanding clinical response (PR 53.7%, SD 27.9%). Toxicities with daily dose of 400 mg and 600 mg, all patients had grade 1 or 2 toxicity. Grade 3 or higher toxicities occurred in 21.1% including edema, neutropenia, nausea, dermatitis, hepatitis and gastrointestinal hemorrhage. The drug was relatively safe overall.
Chemotherapy Division, Cancer Institute Hospital.
Nobuyuki
N
Mizunuma
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016503:Drug Delivery Systems; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate